Start the conversation
Even with some new streamlining recently crafted by the U.S. Food and Drug Administration (FDA), the pathway to new drug approvals is a long and expensive one. The Tufts Center for the Study of Drug Development recently said that it now takes a decade and a staggering $2.9 billion to bring a new drug to market.
The payoffs, of course, can be huge.
As a biotech investor, you like to find firms that are doing all they can to traverse that risk - and find a payoff.
This is premium content for Private Briefing subscribers only.